Hostname: page-component-cd9895bd7-lnqnp Total loading time: 0 Render date: 2024-12-25T19:35:20.306Z Has data issue: false hasContentIssue false
  • English
  • Français

The promises and pitfalls of pharmacoeconomics in schizophrenia

Published online by Cambridge University Press:  16 April 2020

Anita Patel
Anita Patel*
Affiliation:
Institute of Psychiatry, Centre for the Economics of Mental Health, Box PO24 The David Goldberg De Crespigny Park, London, UK
*
*Corresponding author. E-mail address:a.patel@iop.kcl.ac.uk (A. Patel).
Get access

Extract

Pharmacoeconomic studies are often performed in order to evaluate the cost-effectiveness of different treatments in clinical practice. Such studies are exerting an increasingly important influence on treatment choices in all areas of medicine, including psychiatry, and reflect the desire to contain rising costs of medical care [27]. Pharmacoeconomic analyses indicating cost savings can even be a prerequisite for inclusion of a new drug on national formularies [28].

Type
Research Article
Information
European Psychiatry , Volume 18 , Issue S2: Schizophrenia: Improving the treatment through increased understanding - Mind Matters 4th International Psychiatry Forum , December 2003 , pp. 62s - 67s
Copyright
Copyright © 2003 European Psychiatric Association

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Almond, S, O'Donnell, O.Cost analysis of the treatment of schizophrenia in the UK: a comparison of olanzapine and haloperidol. Pharmacoeconomics 1998; 13: 575–88.CrossRefGoogle ScholarPubMed
Almond, S, O'Donnell, O.Cost analysis of the treatment of schizophrenia in the UK. A simulation model comparing olanzapine, risperidone and haloperidol. Pharmacoeconomics 2000; 17: 383–9.CrossRefGoogle Scholar
Awad, AG, Voruganti, LN, Heslegrave, RJ. Measuring quality of life in patients with schizophrenia. Pharmacoeconomics 1997; 11: 32–47.CrossRefGoogle ScholarPubMed
Awad, AG, Voruganti, LN. Quality of life and new antipsychotics in schizophrenia. Are patients better off? Int J Soc Psychiatr 1999; 45: 268–75.CrossRefGoogle ScholarPubMed
Bhana, N, Foster, RH, Olney, R, Plosker, GL. Olanzapine: an updated review of its use in the management of schizophrenia. Drugs 2001; 61: 111–61.CrossRefGoogle ScholarPubMed
Cohen, LJ.Looking beyond the formulary budget in cost-benefit analysis. Am J Managed Care 1997; 3 Suppl: S11–7.Google ScholarPubMed
Edgell, ET, Andersen, SW, Johnstone, BM, Dulisse, BK, Revichi, D, Breier, A.Olanzapine versus risperidone: a prospective comparison of clinicial and economic outcomes in schizophrenia. Pharmacoeconomics 2000; 18: 567–79.CrossRefGoogle Scholar
Foster, RH, Goa, KL. Olanzapine. A pharmacoeconomic review of its use in schizophrenia. Pharmacoeconomics 1999; 15: 611–40CrossRefGoogle Scholar
Foster, RH, Goa, KL. Risperidone. A pharmacoeconomic review of its use in schizophrenia. Pharmacoeconomics 1998;14: 97–133.CrossRefGoogle Scholar
Hamann, J, Leucht, S, Kissling, W.Are the second-generation antipsychotics cost-effective? A critical review on the background of different health systems. Pharmacopsychiatry 2003; 36: 18–26.CrossRefGoogle ScholarPubMed
Hamilton, SH, Revicki, DA, Edgell, ET, Genduso, LA, Tollefson, G.Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia. Results from a randomised clincial trial. Pharmacoeconomics 1999; 15: 469–80.CrossRefGoogle Scholar
Hargreaves, WA, Shumway, M.Pharmacoeconomics of antipsychotic drug therapy. J Clin Psychiatr 1996; 57 (Suppl 9): 66–76.Google ScholarPubMed
Knapp, M.Costs of schizophrenia. B J Psychiatr 1997; 171: 509–18.CrossRefGoogle ScholarPubMed
Knapp, M.Schizophrenia costs and treatment cost-effectiveness. Acta Psychiatrica Scand Supplementum 2000; 102: 5–8.Google Scholar
Marder, SR.Facilitating compliance with antipsychotic medication. J Clin Psychiatr 1998; 59 Suppl. 3): 21–5.Google ScholarPubMed
Meenan, RT, Goodman, MJ, Fishman, PA, Hornbrook, MC, O'Keeffe-Rosetti, MC, Bachman, DJ. Issues in pooling administrative data for economic evaluation. Am J Manag Care 2002; 8: 45–53.Google ScholarPubMed
Meltzer, H.Outcome in schizophrenia: beyond symptom reduction. J Clin Psychiatr 1999; 60(Suppl. 3): 3–7Google ScholarPubMed
Moller, HJ.Management of the negative symptoms of schizophrenia: new treatment options. CNS Drugs 2003; 17(11): 783–823Google ScholarPubMed
Neumann, PJ.Methods of cost-effectiveness analysis in the evaluation of new antipsychotics: implications for schizophrenia treatment. J Clin Psychiatr 1999; 60 (Suppl. 3): 9–14.Google ScholarPubMed
NICE. Guidance on the use of newer (atypical) antipsychotic drugs for the treatment of schizophrenia. Technology Assessment Guidance - No. 43. National Institute for Clinical Excellence, June 2002.Google Scholar
Nicholls, CJ, Hale, AS, Freemantle, N.Cost-effectiveness of amisulpride compared with risperidone in patients with schizophrenia. J Drug Assess 2003; 6: 79–89.Google Scholar
Oh, PI, Iskedjian, M, Addis, A, Lanctot, K, Einarson, TR. Pharmacoeconomic evaluation of clozapine in treatment-resistant schizophrenia: a costutility analysis. Can J Clin Pharmacol 2001; 8: 1999–206.Google Scholar
Palmer, CS, Brunner, E, Ruiz-FIores, LG, Paez-Agraz, F, Rivichi, DA. A cost-effectiveness clinical decision analysis model for treatment of Schizophrenia. Arch Med Research 2002; 33: 572–80.CrossRefGoogle ScholarPubMed
Patel, A, Knapp, M.Costs of mental illness in England. Mental Health Res Rev 1998; 5: 4–10.Google Scholar
Revicki, DA.Cost effectiveness of the newer atypical antipsychotics: a review of the pharmacoeconomic research evidence. Curr Opinion Investigational Drugs 2001;2: 110–7.Google ScholarPubMed
Revicki, DA.Pharmacoeconomic evaluation of treatments for refractory schizophrenia: clozapine-related studies. J Clin Psychiatr 1999,60 (Suppl. 1): 7–11.Google ScholarPubMed
Revicki, DA.Pharmacoeconomic studies of atypical antipsychotic drugs for the treatment of schizophrenia. Schizophrenia Research 1999;35: S101–9.CrossRefGoogle ScholarPubMed
Rey, JA.Antipsychotic therapy: a pharmacoeconomic perspective Am J Health-System Pharmacy 2002;59(22; Suppl 8): S5–9CrossRefGoogle ScholarPubMed
Rupp, A, Keith, SJ. The costs of schizophrenia: assessing the burden. Psychiatric Clin North Am 1993; 16: 413–23.CrossRefGoogle ScholarPubMed
Taylor, DM, Wright, T, Libretto, SE. Risperidone compared with olanzapine in a naturalistic clinical study: a cost analysis. J Clin Psychiatr 2003;64: 589–97.CrossRefGoogle Scholar
Tilden, D, Aristides, M, Meddis, D, Burns, T.An economic assessment of quetiapine and haloperidol in patients with schizophrenia only partially responsive to conventional antipsychotics. Clinical Therapeutics 2002;24: 1648–67.CrossRefGoogle ScholarPubMed
Tunis, SL, Johnstone, BM, Gibson, PJ, Loosbrock, DL, Dulisse, BK. Changes in perceived health and functioning as a cost-effectiveness measure for olanzapine versus haloperidol treatment of schizophrenia. J Clin Psychiatr 1999; 60 (Suppl 19): 38-45.Google ScholarPubMed
Vass, A.NICE guidance "a real victory" for people with schizophrenia. National Inst Clin Excellence BMJ 2002,324(7351): 1413.Google ScholarPubMed
Voruganti, LN, Heslegrave, RJ, Awad, AG, Seeman, MV. Quality of life measurement in schizophrenia: reconciling the quest for subjectivity with the question of reliability. Psychological Medicine 1998; 28: 65–72.CrossRefGoogle ScholarPubMed
Waddington, JL, O'Callaghan, E.What makes an antipsychotic atypical? Conserving the definition. CNS Drugs 1997, 7: 341–6CrossRefGoogle Scholar
Wyatt, RJ, Henter, I, Leary, MC, Taylor, E.An economic evaluation of schizophrenia-1991. Social Psychiatry & Psychiatric Epidemiology 1995;30: 196–205.Google Scholar
Submit a response

Comments

No Comments have been published for this article.